인사이트
Insights From Our Experts
Articles
Webinar: Discover Patient Support Program Needs for Patients with Rare Diseases
In a world where patients face more medication barriers than ever, patient support programs for rare disease patients are critical in providing value-based care that yields a palpable and lasting impact. Manufacturers are acutely aware that…
Getting Treatments to Patients When They Need Them Most: Next Gen Commercialization in Oncology
Commercializing oncology products is extremely complex, but successfully launching new therapies to market is essential for patients and providers in the fight against cancer. In 2020, about 10 million people died from cancer, proving even in…
Driving Commercial Excellence for CAR-T
In this session from the 6th Annual CAR-TCR Summit, Faruk Abdullah, Head of U.S. Consulting, EVERSANA™ MANAGEMENT CONSULTING and Maria Kirsch, SVP & Head of Patient Services share insight on building the future commercialization model designed…
Fearless in Pharma: Addressing Unmet Medical Needs Through Bold Innovation
5,789 new oncology products are currently in development, with 3,677 in phases I and II. Science continues to evolve and provide more patients life-changing therapies, but the commercialization model of these new therapies has not changed…
PharmaVOICE Webinar: Next Gen Commercialization Model for Oncology
In a new 60-minute virtual panel, “Next Gen Commercial Models in Oncology,” PharmaVOICE Editor Taren Grom sat down with industry leaders to discuss how changing market dynamics and a rich pipeline in oncology are creating a…
High-Efficiency Commercialization for High-Science Brands
High-stake or complex therapies, such as cell and gene therapies, immunotherapies and RNA interference (RNAi), have the potential to change the course of treatment for cancer patients and patients with rare diseases. But first, pharma companies must work with providers to navigate patient access complications…
Leadership Briefing – The U.S. Pharmaceutical Market Outlook: The Path to Recovery and the New Normal
During a recent webinar panel, EVERSANA and Reuters gathered industry leaders to discuss the tough questions facing pharma, specifically in the wake of a new U.S. presidency. EVERSANA CEO Jim Lang; Joe Jimenez, Ex-Novartis CEO and…
Do Germany’s New Hemophilia Regulations Have Wider-Reaching Implications?
In July 2019, the Drug Safety and Supply Law (GSAV) was passed by Germany’s Higher Chamber of Parliament, bringing about substantial changes to Germany’s health policy. Besides introducing new strategies for biosimilar uptake and cell and…
Is BeNeLuxA Equipped for a Zolgensma Assessment?
The BeNeLuxA initiative is set to take on Zolgensma (onasemnogene abeparvovec), an innovative gene therapy for children under two years old with spinal muscular atrophy (SMA), which was granted conditional approval for use in Europe in…
Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug Administration (FDA)-approved oncolytic biosimilars in the…